Inheritance and expression of mitochondrial DNA point mutations  by Holme, Elisabeth et al.
ELSEVIER Biochimica et Biophysica Acta 1271 (1995) 249-252 
Biochi f c~a et Biophysica A~ta 
Inheritance and expression of mitochondrial DNA point mutations 
Elisabeth Holme a,*, MAr H. Tulinius b, Nils-GiSran Larsson a,l, Anders Oldfors c 
Department ofClinical ChemistD,, Gothenburg Universily, Sahlgren's Hospital, S-413 45 Gothenburg, Sweden 
Department ofPediatrics, Gothenburg Universi~', East Hospital, S-416 85 Gothenburg, Sweden 
Department ofPathology, Gothenburg University, Sahlgren's Hospital, S-413 45 Gothenburg, Sweden 
Abstract 
An important feature of the mitochondrial genom is the occurrence of heteroplasmy and the possibility for transmission to the 
offspring of various proportions of wild-type and mutated mtDNA. We have investigated the proportion of the tRNALys A8344G 
mutation, the tRNALeu(UUR) A3243G mutation, and the ATPase 6 T8993G mutation in patients with MERRF, MELAS, and Leigh's 
syndrome and their maternal relatives. The level of mutated mtDNA in the offspring of carriers of the tRNALys mutation is correlated to 
the level in lymphocytes in the mother and seems to be transmitted by an essentially random mechanism where only a few mtDNA copies 
are founders of the mitochondrial genom in the offspring and the probability that the mutation is not transmitted to the offspring is high 
when the mothers carriers predominantly wild-type mtDNA. However, we found age-related ifferences in the distribution of mutated 
mtDNA in carriers of the tRNALys and tRNALeu mutations, which have to be considered before levels of mutated mtDNA are used for 
prediction of prognosis and transmission of a disorder. 
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1. Introduction 
An important feature of the mitochondrial genom is the 
occurrence of heteroplasmy and the possibility for trans- 
mission to the offspring of various proportions of wild-type 
and mutated mtDNA, which was first noted in studies on 
Holstein cows [1,2]. We found a progressive increase in 
the percentage of deleted mtDNA in muscle with time in 
two patients with Kearns-Sayre syndrome [3]. This finding 
indicated another important feature of the mitochondrial 
genom, i.e., the dynamic character of the mitochondrial 
genom. Further indications of changes with age in the 
proportion of mutant to non-mutant mtDNA has been 
found in MELAS, where a progressive increase in the level 
of mutated mtDNA in muscle compared to blood cells was 
found with increasing age of the patients [4]. It is thus 
obvious that the proportion of mutant to non-mutant 
mtDNA and the risk for occurrence of disease in an 
individual is not only dependent on the dose of mutated 
mtDNA in the zygote but also of subsequent changes in 
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distribution, which may occur at random or may be influ- 
enced by different selective factors throughout life. Since 
heteroplasmy seems to be rare in the general population it 
is reasonable to assume that if mutations occur the mecha- 
nism of inheritance of the mitochondrial genom favours a 
rapid segregation over a few generations of newly mutated 
mtDNA. To account for such a rapid segregation Ashley et 
al. [2] suggested that only a small portion of the mitochon- 
drial population would be founders of the mitochondrial 
population in the offspring. In dealing with patients carry- 
ing heteroplasmic pathogenic point mutations it is essential 
to find out if the mechanism of inheritance is a random 
process or if selective factors are operating that may lead 
to, e.g., anticipation of the disease. In this study results 
from measurements of proportions of mutant o non-mutant 
mtDNA have been compiled in order to get further insight 
into the mechanisms of pathogenesis and inheritance of 
pathogenic heteroplasmic point mutations. 
2. Material and methods 
2.1. Patients 
The families carrying the tRNALys A8344G mutation 
have been described in detail [5,6]. Material from members 
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in these families have in part been reanalysed together 
with analysis of materials from additional family members 
and other patients carrying the same mutation. The fami- 
lies carrying the tRNALeu(UUR) A3243G mutation and 
ATPase T8993G mutation will be described in detail else- 
where. The clinical, morphological nd biochemical evalu- 
ations have been performed as described [7]. 
2.2. Analysis of mtDNA 
PCR based analyses were performed as described [8- 
10]. 32P-labelled oligonucleotide was added before the last 
PCR-cycle. The gels were scanned in a Phosphorlmager 
(Molecular Dynamics) and the proportions of non-mutated 
to mutated mtDNA was determined by ImageQuant soft- 
ware (Molecular Dynamics) using the 'area integration of 
rectangle method' according to the manufacturer. The 
sensitivity of the measurements was 0.3%. 
3. Results 
3.1. Segregation of mutated mtDNA in families carrying 
heteroplasmic point mutations 
In Fig. 1 segregation data in families carrying different 
pathogenic point mutations are shown. The pedigree re- 
suits in Fig. 1A and D show the possibility for a very rapid 
segregation to almost homoplasmy over two to three gen- 
erations for the ATPase 6 T8993G mutation causing 
Leigh's syndrome in the proband and in the RNALys 
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Fig. 2. Muscle-to-lymphocyte ratio of the percentage of the 
tRNALeu(UUR) mutation (A) and the tRNALys A8344G mutation (B) 
versus age of the patient. 
A8344G mutation causing MERRF syndrome with onset 
during childhood in the proband. In the family carrying the 
tRNALeu(UUR) mutation the levels in lymphocytes from 
affected cases (Fig. 1 B) are considerably ower than for the 
other mutations and segregation data based on measure- 
ments in muscle are also shown (Fig. I C). It should be 
noted that increase in the proportion of mutated mtDNA in 
successive generations i not found in all cases and rever- 
sion to the homoplasmic wild-type state is found both in 
the MERRF and MELAS families. In an extended study of 
the family carrying the tRNALys A8344G mutation, which 
includes a branch of the family were there are no cases 
affected by disease (Fig. 1E) no general tendency towards 
increase in the level of mutated mtDNA in successive 
generations i found. In fact reversal to a homoplasmic 
wild type appears to be common when the mother carries 
predominantly wild type mtDNA. 
3.2. Changes in the distribution of mutated and non- 
mutated mtDNA with age 
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Fig. 1. Segregation of mutated mtDNA in families carrying the ATPase 6 
T8993G mutation (A), the tRNALeu(UUR) A3243G mutation (B,C), and 
tRNALys A8344G mutation (D-F). The percentage of mutated mtDNA 
has been measured in lymphocytes (A, B, D-F) and muscle (C). (11) 
Clinically affected, ([]) cases with essentially normal findings on exami- 
nation, and ([]) not investigated. Clinically affected according to history. 
In Fig. 2 the ratio of the percentage of mutated mtDNA 
in muscle to lymphocytes as a function of age is shown for 
carriers of the tRNALeu(UUR) A3243G and tRNALys 
A8344G mutations. In carriers of the A3243G mutation the 
levels of mutated mtDNA in muscle is considerably higher 
than in lymphocytes. When the ratio of muscle to lympho- 
cyte levels are plotted versus age there appears to be a 
dramatic increase in the ratio with age (Fig. 2A). Since the 
level in muscle is high in the younger cases (85% and 
86%) and cannot be substantially increased it cannot be 
expected that their ratios will increase with age unless the 
increasing ratio is totally due to a decrease in the lympho- 
cyte level. In carriers of the A8344G mutation the ratio is 
rather constant during adult life with a tendency to some- 
what higher levels in muscle, which possibly might in- 
crease further late in life. However, in the two investigated 
children the level of mutated mtDNA in lymphocytes i
considerably higher than in muscle and a rapid change in 
distribution of mutated mtDNA seems to take place during 
childhood. 
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In the proband, 1 year of age, and his mother, 27 years 
of age, carrying the ATPase 6 A8993G mutation the ratios 
between muscle and lymphocyte were 0.97 and 1.02. 
4. Discussion 
Taken together the collected segregation data in the 
families carrying mtDNA mutations eem to be compatible 
with an essentially random mode of inheritance of the 
mitochondrial genom where the proportion of mutated to 
non-mutated mtDNA in the offspring is correlated to the 
proportion in the mother. Although it is obvious that the 
collected data may be biased in several ways and the 
number of data is not sufficient for testing different likeli- 
hood-based models for inheritance we have tried to anal- 
yse the data in order to get some insight into the mecha- 
nism of inheritance that eventually could form a base for 
counselling in carriers of pathogenic mtDNA mutations. 
When the inheritance of pathogenic mtDNA mutations 
are studied it is reasonable to assume that a segregation 
pattern that reflects the basic mechanism for inheritance of 
a heteroplasmic mitochondrial genom is most likely to 
occur when the percentage of mutated mtDNA is well 
below the threshold level for impaired oxidative phospho- 
rylation or clinical expression of disease. For the MERRF 
mutation this threshold is about 90% [5,11,12]. We have 
thus chosen to base our speculations on the inheritance of 
the heteroplasmic mitochondrial genom on the branch of 
the MERRF family presented here where there are no 
clinically affected cases and the percentage of mutated 
mtDNA in the mothers is 14-33%. It is obvious that the 
probability for reversal to a homoplasmic wild-type mito- 
chondrial genom is high. In fact 50% of the offspring has 
not inherited the mutated mtDNA at all and 75% of the 
offspring has a lower level of mutated mtDNA than their 
mothers. The fast segregation of the two mtDNA species is 
compatible with a model where only a few molecules of 
mtDNA, in fact as few as 3-4 copies, are founders of the 
mitochondrial genom in the offspring. In carriers of neutral 
mtDNA mutations it would be expected that a correspond- 
ing segregation pattern would occur when the mothers 
carries 67-86% of mutated mtDNA, i.e., the expected 
outcome would be that 75% of the offspring would have a 
higher level of mutant mtDNA than their mothers and 
complete segregation to a homoplasmic mutated genom 
would occur in 50% of the offspring. However, in MERRF 
syndrome homoplasmy of the mutant mtDNA does not 
occur. When this is taken into account he expected out- 
come would be that about 50% of the offspring would get 
a higher percentage of mutated mtDNA than their mothers 
and probably develop MERRF syndrome, which is in a 
fairly good agreement with the actual findings. However, 
this analysis is based on measurements of proportions of 
mutant mtDNA in lymphocytes, collected at about the 
same time, which means that the cases are of successively 
older age with each generation of the pedigree. Although 
there is a fairly constant ratio between muscle and lympho- 
cyte levels during adult life in MERRF it cannot be taken 
for granted that there is no age-dependent change in 
lymphocyte levels and that the measured levels were the 
same at the time of conception. In MELAS syndrome 
where the level of mtDNA in muscle differs substantially 
from the level in lymphocytes and the difference seems to 
increase with age both compared to whole-blood DNA [4] 
and lymphocytes it is obvious that it has to be found out 
by prospective studies how these changes occur. The seg- 
regation data based on lymphocyte levels in our MELAS 
family is very similar to the data in MERRF with respect 
to the distribution pattern of the values, although the 
values are generally lower. 
In MELAS and in MERRF there is accumulation of 
abnormal mitochondria in muscle and a high level of 
mutated mtDNA in muscle is generally found in patients 
that express the disease [5,9,12]. Since age-dependent 
changes in the level of mutated mtDNA occurs it is our 
believe that onset of symptoms occurs when the level of 
mutated mtDNA has reached the threshold level for ex- 
pression of disease. Onset of disease often occurs during 
adolescence or adult life and it seems unlikely that a level 
of mutated mtDNA that causes severe impairment in ox- 
idative phosphorylation would have passed without symp- 
toms until adolescence or adult life. We are thus inclined 
to believe that in MELAS the level in lymphocytes is 
closer to the inherited dose of mutant mtDNA than the 
muscle level and that the increasing ratio of muscle to 
lymphocyte levels is mainly due to increase in the muscle 
level. 
In MERRF the occurrence of rapidly growing lipomas 
with high levels of mutated mtDNA [6] indicates that in 
some tissues clones with a high level of mutated mtDNA 
are favoured. During childhood there is a rapid growth of 
the lymphoid tissue. Is the high level in lymphocytes in 
MERRF during childhood due to expansion of lymphocyte 
clones with a high percentage of mutated mtDNA, which 
precedes a more slowly increase in muscle that eventually 
will catch up and reach about the same level? If this is the 
case - -  i.e., that the actual inherited ose of the MERRF 
mutation is substantially lower than is indicated by the 
findings in adults and is closer to the blood DNA level 
found in MELAS - -  there must be specific mechanisms 
that selects for these mutations, which in part may be 
inherent o the tissue but also may be due to nuclear traits 
that in part may determine the clinical phenotypes of these 
disorders. Consequently, it is obvious that the model for 
inheritance discussed above does not reflect the actual 
mechanism for inheritance of a heteroplasmic mitochon- 
drial genom. From a clinical point of view the actual 
mechanism of inheritance and pathogenesis may not be 
that important if fairly simple likelihood models based on 
measurements in lymphocytes or muscle tissue turns out to 
be valid for prediction of prognosis and transmission of a 
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disorder. However, before any such models can be elabo- 
rated it is obvious that we have to increase our knowledge 
on the age-dependent changes in the level of mutated 
mtDNA and its consequences. 
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